Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

IVVD

Invivyd Inc

Sep 20 • 04:00PM ET

1.20

Dollar change -0.02
Percentage change -1.64	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM IWN VXF SCHA VTWO IWC RSSL VTWV SCHB

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	39.18%	Shs Outstand	110.16M	Perf Week	4.35%
Market Cap	143.33M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	-0.24%	Shs Float	72.65M	Perf Month	36.67%
Income	-203.84M	PEG	-	EPS next Q	-0.33	Inst Own	60.07%	Short Float	10.51%	Perf Quarter	-3.23%
Sales	2.26M	P/S	63.42	EPS this Y	61.33%	Inst Trans	1.52%	Short Ratio	12.15	Perf Half Y	-61.17%
Book/sh	1.18	P/B	1.02	EPS next Y	86.43%	ROA	-82.73%	Short Interest	7.64M	Perf Year	-31.43%
Cash/sh	1.24	P/C	0.97	EPS next 5Y	-	ROE	-96.56%	52W Range	0.81 - 5.20	Perf YTD	-69.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-144.93%	52W High	-76.90%	Beta	0.63
Dividend TTM	-	Quick Ratio	4.57	Sales past 5Y	0.00%	Gross Margin	5.04%	52W Low	47.86%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.71	EPS Y/Y TTM	-12.04%	Oper. Margin	-9326.33%	RSI (14)	60.11	Volatility	7.60% 12.51%
Employees	94	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-9003.40%	Recom	1.50	Target Price	8.65
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	13.75%	Payout	-	Rel Volume	1.98	Prev Close	1.22
Sales Surprise	-54.72%	EPS Surprise	-7.15%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	628.20K	Price	1.20
SMA20	20.84%	SMA50	11.46%	SMA200	-52.31%	Trades		Volume	1,244,499	Change	-1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-05-24	Upgrade	Guggenheim	Neutral → Buy	$9
Mar-26-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$4 → $10
Dec-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$1 → $4
May-01-23	Initiated	H.C. Wainwright	Buy	$5

Sep-12-24 07:01AM	Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19 (GlobeNewswire) +12.75%
Sep-05-24 07:01AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-04-24 07:01AM	Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA (GlobeNewswire)
Sep-03-24 07:01AM	Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest (GlobeNewswire)
Aug-27-24 07:01AM	Invivyd Announces PEMGARDA (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial (GlobeNewswire) -28.67%
02:43AM	Loading…
Aug-15-24 02:43AM	Q2 2024 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) +6.12%
Aug-14-24 09:10AM	Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.55%
08:01AM	Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-12-24 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.31% +9.84%
Jul-01-24 07:01AM	Invivyd Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) +9.09%
Jun-14-24 07:01AM	Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants (GlobeNewswire) -7.06%
Jun-03-24 04:01PM	Invivyd to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-24 07:05AM	Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies (GlobeNewswire)
07:00AM	Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer (GlobeNewswire)
May-29-24 07:00AM	Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) (GlobeNewswire)
07:00AM	Loading…
May-22-24 07:00AM	Invivyd Elects Two New Independent Members to its Board of Directors (GlobeNewswire)
May-13-24 04:01PM	Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
10:44AM	Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:25PM	Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis (GuruFocus.com) -6.61%
May-09-24 10:56PM	IVVD Stock Earnings: Invivyd Meets EPS for Q1 2024 (InvestorPlace)
04:01PM	Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-07-24 07:30AM	Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback (GlobeNewswire) +6.36%
May-02-24 05:13PM	Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Apr-30-24 07:30AM	Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position (GlobeNewswire) +6.73%
Apr-15-24 07:30AM	Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA (GlobeNewswire)
Apr-12-24 07:30AM	Invivyd Announces CEO Transition (GlobeNewswire)
Apr-04-24 04:01PM	Invivyd Provides PEMGARDA Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million (GlobeNewswire) -8.91% -7.82%
Mar-28-24 01:53PM	IVVD Stock Earnings: Invivyd Misses EPS for Q4 2023 (InvestorPlace) +11.00%
07:00AM	Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-22-24 03:28PM	Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial (GlobeNewswire) +41.10%
03:04PM	Loading…
03:04PM	Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 (GlobeNewswire)
Feb-05-24 04:02PM	Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace) +11.31%
Jan-12-24 12:00PM	All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy (Zacks)
Jan-03-24 07:00AM	Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents (GlobeNewswire)
Dec-23-23 05:29AM	Invivyd Stock More Than Doubled Last Week. Is It Too Late to Buy? (Motley Fool)
Dec-19-23 11:52AM	Invivyd (IVVD) Surges on Positive Data From COVID-19 Study (Zacks) -7.52%
Dec-18-23 07:00AM	Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 (GlobeNewswire) +120.25%
Nov-13-23 10:21AM	Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Nov-10-23 08:35AM	Q3 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:01PM	Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire) -7.89%
Nov-02-23 04:01PM	Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +5.44%
Oct-31-23 04:01PM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.96%
Sep-11-23 07:00AM	Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 (GlobeNewswire)
Sep-06-23 08:17PM	7 Biotech Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
07:00AM	Invivyd to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-05-23 07:00AM	Invivyd Appoints William Duke as Chief Financial Officer (GlobeNewswire)
Aug-29-23 01:13PM	Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why (Zacks)
Aug-15-23 05:45AM	Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:43AM	Q2 2023 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:01PM	Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Aug-03-23 04:01PM	Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Jul-27-23 04:01PM	Invivyd Announces Appointment of Sara Cotter to Board Of Directors (GlobeNewswire)
Jul-17-23 02:15PM	Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People (Benzinga)
07:00AM	Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-26-23 07:00AM	Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19 (GlobeNewswire)
Jun-22-23 01:07PM	Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19 (Benzinga) -6.19%
07:00AM	Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People (GlobeNewswire)
Jun-01-23 07:00AM	Invivyd to Participate at the Jefferies Healthcare Conference (GlobeNewswire) -16.67%
May-23-23 06:25AM	Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans? (Simply Wall St.) +19.72%
May-11-23 04:01PM	Invivyd Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
May-04-23 04:01PM	Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Apr-25-23 04:01PM	Invivyd to Participate at H.C. Wainwrights BioConnect Investor Conference (GlobeNewswire)
07:00AM	Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update (GlobeNewswire)
Apr-14-23 09:35AM	After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD) (Zacks)
Apr-12-23 07:00AM	Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer (GlobeNewswire)
Mar-30-23 04:01PM	Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19 (GlobeNewswire) -8.14%
Mar-28-23 04:58AM	Invivyd, Inc. (NASDAQ:IVVD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 06:41AM	Full Year 2022 Invivyd Inc Earnings Call (Thomson Reuters StreetEvents) -8.39%
Mar-23-23 04:01PM	Invivyd Reports Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-22-23 04:30PM	Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19 (GlobeNewswire) -9.55%
Mar-16-23 07:00AM	Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 07:00AM	Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies (GlobeNewswire)
Feb-28-23 07:00AM	Invivyd to Participate at Cowens 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-03-23 07:30AM	Invivyd Announces Changes to Executive Team (GlobeNewswire) -7.89%
Jan-27-23 05:59PM	Why Shares of Invivyd Jumped This Week (Motley Fool) -8.47%
Jan-02-23 12:00PM	Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why (Zacks)
Dec-19-22 07:00AM	Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop (GlobeNewswire)
Dec-13-22 02:37PM	We Think Invivyd (NASDAQ:IVVD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-06-22 04:01PM	Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer (GlobeNewswire) -8.45% +5.90%
Nov-22-22 09:20PM	The Petri Dish: J&J vet joins Moderna as U.S. GM; Invivyd partners with investment firm (American City Business Journals)
Nov-17-22 01:58PM	Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies (Insider Monkey)
07:00AM	Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 (GlobeNewswire)
Nov-10-22 04:01PM	Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) +7.55%
Nov-09-22 07:00AM	Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -9.07%
Nov-02-22 07:00AM	Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) -9.88%
Oct-24-22 04:01PM	Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors (GlobeNewswire)
Oct-17-22 02:37PM	Adagio Therapeutics, now Invivyd, retools its strategy after losing two executives (American City Business Journals)
Oct-13-22 04:26PM	Invivyd Names Fred Driscoll as Interim CFO, Cuts Some Positions (The Wall Street Journal) +5.44% -6.02%
04:01PM	Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform (GlobeNewswire)
Oct-12-22 04:01PM	Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022 (GlobeNewswire)
Oct-03-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews David Hering CEO, Invivyd Inc. (ACCESSWIRE)

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCGUIRE TERRANCE	Director	May 29 '24	Sale	1.66	112,381	186,575	4,688,079	May 31 05:09 PM
Adimab, LLC	10% Owner	Jan 19 '24	Sale	3.95	5,000,000	19,750,000	21,687,906	Jan 22 04:18 PM

Open in Screener

ALEC

Alector Inc

Sep 20 • 04:00PM ET

5.75

Dollar change -0.39
Percentage change -6.35	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI XBI VXF IWO IBB SCHA VTWO VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	21.73%	Shs Outstand	84.88M	Perf Week	-4.64%
Market Cap	559.59M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-0.79%	Shs Float	76.18M	Perf Month	8.70%
Income	-160.66M	PEG	-	EPS next Q	-0.53	Inst Own	73.32%	Short Float	4.55%	Perf Quarter	25.82%
Sales	55.27M	P/S	10.12	EPS this Y	-22.79%	Inst Trans	0.69%	Short Ratio	6.02	Perf Half Y	-7.70%
Book/sh	1.55	P/B	3.72	EPS next Y	27.59%	ROA	-25.11%	Short Interest	3.47M	Perf Year	-5.27%
Cash/sh	5.17	P/C	1.11	EPS next 5Y	-10.70%	ROE	-92.64%	52W Range	3.66 - 8.90	Perf YTD	-27.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.76%	ROI	-90.22%	52W High	-35.39%	Beta	0.68
Dividend TTM	-	Quick Ratio	3.52	Sales past 5Y	158.96%	Gross Margin	83.56%	52W Low	57.10%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	3.52	EPS Y/Y TTM	-4.52%	Oper. Margin	-338.94%	RSI (14)	54.94	Volatility	7.62% 6.46%
Employees	244	Debt/Eq	0.24	Sales Y/Y TTM	-45.84%	Profit Margin	-290.66%	Recom	1.82	Target Price	13.75
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-2539.63%	Payout	-	Rel Volume	2.72	Prev Close	6.14
Sales Surprise	5.02%	EPS Surprise	20.16%	Sales Q/Q	-73.17%	Earnings	Aug 07 AMC	Avg Volume	576.13K	Price	5.75
SMA20	7.45%	SMA50	4.34%	SMA200	-1.51%	Trades		Volume	1,565,737	Change	-6.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Upgrade	Stifel	Hold → Buy	$8 → $15
Dec-12-23	Initiated	Deutsche Bank	Buy	$12
Sep-25-23	Initiated	Goldman	Sell	$4
Sep-22-23	Initiated	Cantor Fitzgerald	Overweight	$13
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$24 → $12
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27 → $13
Jul-07-22	Initiated	Mizuho	Buy	$15
Apr-13-22	Initiated	Goldman	Sell	$9
Mar-08-22	Downgrade	Stifel	Buy → Hold	$32 → $18
Sep-27-21	Initiated	William Blair	Outperform
Jan-15-21	Resumed	BofA Securities	Buy	$35
Jun-24-20	Initiated	H.C. Wainwright	Buy	$41
Apr-28-20	Initiated	Goldman	Buy	$32
Mar-06-20	Initiated	Citigroup	Buy	$40
Feb-27-20	Initiated	Barclays	Overweight	$36
Feb-19-20	Initiated	Stifel	Buy	$44
Nov-21-19	Initiated	BTIG Research	Buy	$28
Mar-04-19	Initiated	SVB Leerink	Outperform
Mar-04-19	Initiated	Morgan Stanley	Overweight	$27
Mar-04-19	Initiated	BofA/Merrill	Buy	$26

Show Previous Ratings

Sep-19-24 08:00AM	Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) (GlobeNewswire) +8.87%
Aug-29-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-23-24 07:19PM	Director Richard Scheller Sells 44,250 Shares of Alector Inc (ALEC) (GuruFocus.com)
Aug-07-24 06:15PM	Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:11PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Alector Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 04:05PM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-28-24 08:05AM	Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference 2024 (AAIC ) (GlobeNewswire)
Jul-23-24 07:00AM	Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference (AAIC ) 2024 (GlobeNewswire)
Jun-29-24 08:43PM	Why Did Analysts Give Alector, Inc. (ALEC) a Moderate Buy Rating? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-20-24 07:00AM	Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-10-24 07:00AM	Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform (GlobeNewswire)
Jun-03-24 07:00AM	Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-09-24 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
11:55PM	Loading…
May-08-24 11:55PM	ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:25PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:19PM	Alector: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know (Zacks) -8.38%
Feb-28-24 02:02PM	Q4 2023 Alector Inc Earnings Call (Thomson Reuters StreetEvents)
10:13AM	Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Feb-27-24 04:46PM	Alector Inc (ALEC) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +8.18%
04:23PM	Alector: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-20-24 04:05PM	Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call (GlobeNewswire)
10:00AM	Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline (Zacks)
Feb-08-24 07:00AM	Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease (GlobeNewswire)
06:48AM	Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength? (Zacks)
07:00AM	Loading…
Feb-07-24 07:00AM	FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire) +5.96%
Jan-25-24 12:00PM	Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jan-23-24 07:32AM	Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs (InvestorPlace)
Jan-19-24 09:20AM	Alector Announces Closing of Public Offering (GlobeNewswire)
Jan-17-24 08:54AM	Alector Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -14.01%
Jan-16-24 04:01PM	Alector Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-08-24 01:25PM	Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 (Investor's Business Daily) +7.34%
Dec-05-23 09:55AM	Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet (Zacks)
Nov-28-23 07:00AM	Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs (GlobeNewswire)
Nov-14-23 09:35AM	Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +14.06%
Nov-08-23 07:00AM	Alector to Participate in the Stifel Healthcare Conference (GlobeNewswire) -7.30%
Nov-07-23 06:02PM	Alector: Q3 Earnings Snapshot (Associated Press Finance) +5.12%
05:11PM	Alector Inc (ALEC) Reports Q3 2023 Financial Results with Key Clinical Advancements (GuruFocus.com)
04:05PM	Alector Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-23 07:00AM	Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN) (GlobeNewswire)
Sep-14-23 01:12AM	10% Owner Polaris Venture Management Co. VI, L.L.C. Sells 500,000 Shares of Alector Inc (GuruFocus.com)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
Sep-07-23 07:00AM	Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimers Disease (GlobeNewswire) +6.76%
Aug-31-23 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Aug-10-23 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade (Zacks)
Aug-03-23 05:45PM	Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +32.38%
04:43PM	Alector: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Alector Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-23 08:30AM	Alector to Host Mid-Year Earnings Conference Call (GlobeNewswire)
Jul-13-23 01:29PM	7 Stocks That AI Says Will Make You a Millionaire by 2025 (InvestorPlace)
Jun-06-23 07:00AM	Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Companies Like Alector (NASDAQ:ALEC) Are In A Position To Invest In Growth (Simply Wall St.) -8.20%
May-09-23 09:55AM	Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect? (Zacks)
May-05-23 06:31AM	Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price (Simply Wall St.) +10.27%
May-04-23 07:35PM	Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:27PM	Alector: Q1 Earnings Snapshot (AP Finance)
04:05PM	Alector Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 07:00AM	Alector to Participate in the BofA Securities 2023 Healthcare Conference (GlobeNewswire)
May-01-23 10:01AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-27-23 10:03AM	Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-13-23 12:59PM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested three years ago (Simply Wall St.)
08:30AM	Are Options Traders Betting on a Big Move in Alector (ALEC) Stock? (Zacks)
Mar-01-23 04:05PM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) -6.36%
Feb-28-23 04:05PM	Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-20-23 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-17-23 06:01AM	Alector, Inc. (NASDAQ:ALEC) is a favorite amongst institutional investors who own 64% (Simply Wall St.)
Feb-16-23 10:01AM	Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Dec-21-22 05:01AM	We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate (Simply Wall St.)
Dec-08-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-22 11:05AM	Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Nov-10-22 05:13AM	Alector Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) +19.62%
Nov-08-22 07:45PM	Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -19.81%
04:05PM	Alector Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire)
Nov-04-22 11:05AM	Alector (NASDAQ:ALEC) investors are sitting on a loss of 65% if they invested a year ago (Simply Wall St.)
Nov-03-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-13-22 08:00AM	Alector Announces Promotion of Clare Hunt to Chief People Officer (GlobeNewswire)
Oct-06-22 04:30PM	Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-22 07:00AM	Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimers Disease (AD) (GlobeNewswire) +5.66%
Sep-07-22 07:00AM	Alector to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +8.28%
Aug-09-22 09:55AM	Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to Trade (Zacks)
Aug-06-22 08:33AM	Alector, Inc.'s (NASDAQ:ALEC) Stock Is Going Strong: Have Financials A Role To Play? (Simply Wall St.)
Aug-04-22 07:15PM	Alector (ALEC) Q2 Earnings and Revenues Beat Estimates (Zacks) +15.27%
04:05PM	Alector Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-08-22 10:54AM	AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector (Benzinga)
Jul-07-22 05:59PM	Alzheimer's drug cut loose from Peninsula biotech's collaboration but another survives (American City Business Journals)
Jun-08-22 07:00AM	Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
May-28-22 08:20AM	Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested a year ago (Simply Wall St.)
May-27-22 04:30PM	Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules (GlobeNewswire)
May-05-22 06:25PM	Alector (ALEC) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.67% -6.51%
04:05PM	Alector Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-04-22 07:00AM	Alector to Participate at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
May-02-22 07:47AM	New Strong Sell Stocks for May 2nd (Zacks)
Apr-27-22 03:03PM	Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Mar-29-22 04:05PM	Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRASSO MARC	Chief Financial Officer	Sep 03 '24	Sale	4.88	7,297	35,620	130,740	Sep 04 04:44 PM
Rosenthal Arnon	Chief Executive Officer	Sep 03 '24	Sale	4.88	26,499	129,387	1,948,746	Sep 04 04:15 PM
Kenkare-Mitra Sara	President and Head of R&D	Sep 03 '24	Sale	4.88	13,926	67,981	291,715	Sep 04 04:15 PM
Romano Gary	Chief Medical Officer	Sep 03 '24	Sale	4.88	8,478	41,385	179,795	Sep 04 04:15 PM
Arnon Rosenthal	Officer	Sep 03 '24	Proposed Sale	5.28	24,359	128,616		Aug 30 05:18 PM
Sara Kenkare-Mitra	Officer	Sep 03 '24	Proposed Sale	5.28	12,796	67,563		Aug 30 05:18 PM
Marc Grasso	Officer	Sep 03 '24	Proposed Sale	5.28	6,703	35,392		Aug 30 05:18 PM
Gary Romano	Officer	Sep 03 '24	Proposed Sale	5.28	7,788	41,121		Aug 30 05:18 PM
SCHELLER RICHARD H	Director	Aug 22 '24	Sale	5.16	44,250	228,388	35,000	Aug 23 04:05 PM
SCHELLER RICHARD H	Director	Aug 22 '24	Proposed Sale	4.75	44,250	210,188		Aug 22 05:31 PM
Hammond Paula	Director	Aug 12 '24	Sale	5.06	10,500	53,179	60,209	Aug 13 07:55 PM
Yaffe Kristine	Director	Aug 12 '24	Sale	5.06	5,000	25,309	67,709	Aug 13 07:55 PM
PAULA HAMMOND	Director	Aug 12 '24	Proposed Sale	5.06	10,500	53,179		Aug 12 04:34 PM
Romano Gary	Chief Medical Officer	Jun 03 '24	Sale	4.80	8,040	38,582	188,273	Jun 04 06:05 PM
Kenkare-Mitra Sara	President and Head of R&D	Jun 03 '24	Sale	4.80	13,206	63,373	305,641	Jun 04 06:05 PM
Rosenthal Arnon	Chief Executive Officer	Jun 03 '24	Sale	4.80	25,135	120,618	1,975,245	Jun 04 06:05 PM
GRASSO MARC	Chief Financial Officer	Jun 03 '24	Sale	4.80	6,920	33,208	138,037	Jun 04 06:05 PM
GRASSO MARC	Chief Financial Officer	Mar 04 '24	Sale	6.92	5,716	39,562	144,957	Mar 05 06:00 PM
Rosenthal Arnon	Chief Executive Officer	Mar 04 '24	Sale	6.92	18,837	130,386	2,000,380	Mar 05 06:00 PM
Romano Gary	Chief Medical Officer	Mar 04 '24	Sale	6.92	6,001	41,554	196,313	Mar 05 06:00 PM
Kenkare-Mitra Sara	President and Head of R&D	Mar 04 '24	Sale	6.92	10,169	70,387	318,847	Mar 05 06:00 PM
GRASSO MARC	Chief Financial Officer	Dec 04 '23	Sale	5.56	4,574	25,431	150,673	Dec 06 06:30 PM
Romano Gary	Chief Medical Officer	Dec 04 '23	Sale	5.56	5,035	27,995	202,314	Dec 06 06:30 PM
Rosenthal Arnon	Chief Executive Officer	Dec 04 '23	Sale	5.56	23,831	132,500	2,019,217	Dec 06 06:30 PM
Kenkare-Mitra Sara	President and Head of R&D	Dec 04 '23	Sale	5.56	12,519	69,606	329,016	Dec 06 06:30 PM

Open in Screener

CYCN

Cyclerion Therapeutics Inc

Sep 20 • 04:00PM ET

2.93

Dollar change +0.10
Percentage change 3.53	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

CYCN Cyclerion Therapeutics Inc daily Stock Chart

Held by: VXF ONEQ

Index	-	P/E	-	EPS (ttm)	-5.19	Insider Own	23.24%	Shs Outstand	2.47M	Perf Week	1.03%
Market Cap	7.94M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.08M	Perf Month	5.40%
Income	-12.74M	PEG	-	EPS next Q	-	Inst Own	38.74%	Short Float	0.63%	Perf Quarter	32.58%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	20.41%	Short Ratio	2.03	Perf Half Y	4.64%
Book/sh	3.49	P/B	0.84	EPS next Y	-	ROA	-103.82%	Short Interest	0.01M	Perf Year	-19.50%
Cash/sh	1.69	P/C	1.73	EPS next 5Y	-	ROE	-150.23%	52W Range	1.75 - 5.25	Perf YTD	-12.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.06%	ROI	-145.10%	52W High	-44.19%	Beta	1.91
Dividend TTM	-	Quick Ratio	3.68	Sales past 5Y	-33.97%	Gross Margin	-	52W Low	67.42%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	3.68	EPS Y/Y TTM	60.58%	Oper. Margin	0.00%	RSI (14)	49.93	Volatility	4.69% 7.67%
Employees	1	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	71.25%	Payout	-	Rel Volume	0.53	Prev Close	2.83
Sales Surprise	-13.92%	EPS Surprise	-3.33%	Sales Q/Q	-	Earnings	-	Avg Volume	6.45K	Price	2.93
SMA20	0.79%	SMA50	-3.54%	SMA200	-1.36%	Trades		Volume	3,409	Change	3.53%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-21	Initiated	Truist	Buy	$14
Sep-24-21	Initiated	Cantor Fitzgerald	Overweight	$7
Jun-03-19	Initiated	Credit Suisse	Neutral

Aug-07-24 07:00AM	Regina Graul, Ph.D., Promoted to Chief Executive Officer (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +17.98%
May-08-24 08:52AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-05-24 06:53AM	CYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
08:00AM	Loading…
Dec-04-23 08:00AM	Cyclerion Appoints Regina Graul, Ph.D., as President (GlobeNewswire) -8.71%
Nov-30-23 06:16PM	Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator (GlobeNewswire) +7.39% +14.06%
Aug-02-23 08:39PM	The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets (American City Business Journals)
Jul-31-23 07:00AM	Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets (GlobeNewswire) +14.15%
Jun-01-23 04:00PM	Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-15-23 01:00PM	Cyclerion Announces Reverse Stock Split (GlobeNewswire) -14.34%
May-12-23 02:59PM	Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors (Benzinga) -25.10%
May-11-23 06:00PM	Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 (GlobeNewswire)
06:00PM	Cyclerion Announces Corporate Updates and Q1 2023 Financial Results (GlobeNewswire)
Apr-03-23 07:30AM	Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement (GlobeNewswire) -17.98%
07:00AM	Loading…
Mar-27-23 07:00AM	Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases (GlobeNewswire) +23.71%
Mar-22-23 04:40PM	Cyclerion Reports Corporate Update and Full Year 2022 Financial Results (GlobeNewswire) -11.54%
Nov-22-22 07:00AM	Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company (GlobeNewswire) +34.31%
Nov-09-22 06:34AM	Cyclerion Therapeutics Third Quarter 2022 Earnings: US$0.24 loss per share (vs US$0.26 loss in 3Q 2021) (Simply Wall St.)
Oct-07-22 02:31PM	Cyclerion Therapeutics lays off nearly half of workforce (American City Business Journals) -9.66%
Oct-06-22 12:46PM	Cyclerion Shares Fall After Reprioritized Pipeline, Workforce Reduction (Benzinga) -37.57%
08:00AM	Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy (GlobeNewswire)
Aug-09-22 05:35PM	Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -17.39%
04:00PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 09:22AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? (Simply Wall St.) +27.76%
Jul-28-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS) (GlobeNewswire) +22.08%
Jul-26-22 07:00AM	Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics Board of Directors (GlobeNewswire)
Jun-28-22 09:00AM	Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire) -5.55%
Jun-22-22 08:30AM	Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation (GlobeNewswire)
Jun-17-22 11:20AM	Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies (Benzinga)
08:00AM	Loading…
08:00AM	Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease (GlobeNewswire)
Jun-10-22 07:00AM	Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) -20.18%
Jun-06-22 07:00AM	Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium (GlobeNewswire) +8.58%
May-11-22 09:30AM	As Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) drops to US$26m market cap, insiders might rethink their US$2.7m stock purchase earlier this year (Simply Wall St.) -8.17%
May-04-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results (GlobeNewswire) +8.62% -5.39%
Feb-27-22 06:39AM	Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-24-22 04:01PM	Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates (GlobeNewswire)
Feb-23-22 08:00AM	Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration (GlobeNewswire)
Feb-01-22 05:30AM	CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board (GlobeNewswire) +9.09%
Jan-26-22 08:00AM	Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimers Disease with Vascular Pathology (GlobeNewswire)
Dec-15-21 10:00AM	Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN) (Zacks) +9.38%
Nov-25-21 04:47AM	Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) insider upped their holding by 67% earlier this year (Simply Wall St.)
Nov-11-21 05:32PM	Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Nov-09-21 04:01PM	Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -5.42%
Nov-08-21 12:00PM	Exclusive: Startup raises $27M to find brain-based biomarkers (American City Business Journals)
Oct-20-21 04:24PM	Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside (Benzinga) +10.90% -5.42%
Oct-11-21 03:34AM	David Greenspans Slate Path Capital is Buying Coinbase, Stitch Fix, and More (Insider Monkey)
Oct-10-21 09:37AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Sep-22-21 08:00AM	Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator (GlobeNewswire)
Sep-08-21 08:00AM	Cyclerion Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-26-21 07:19AM	Cyclerion Therapeutics (NASDAQ:CYCN) Has Debt But No Earnings; Should You Worry? (Simply Wall St.)
Aug-23-21 05:00PM	Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimers Disease Summit (GlobeNewswire) +8.16%
Jul-29-21 05:00PM	Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) -12.54%
Jul-22-21 04:30PM	Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimers Disease with Vascular Pathology at the Alzheimers Association International Conference 2021 (AAIC) (GlobeNewswire) +14.72%
Jul-12-21 02:24AM	Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Are Down 31% On Their Shares (Simply Wall St.)
Jul-09-21 06:14AM	Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers (Benzinga)
Jul-08-21 07:22PM	Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership (PR Newswire)
04:30PM	Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership (GlobeNewswire)
Jun-04-21 10:27AM	Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise (Benzinga)
08:00AM	Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat (GlobeNewswire)
08:00AM	Cyclerion Therapeutics Announces $18 Million Private Placement (GlobeNewswire)
May-27-21 04:30PM	Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology (GlobeNewswire) +5.25%
May-25-21 07:00AM	Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-09-21 03:36AM	The CEO & Director of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), Peter Hecht, Just Bought 309% More Shares (Simply Wall St.)
Apr-27-21 09:00AM	Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress (GlobeNewswire) -17.95%
Apr-26-21 07:00AM	Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors (GlobeNewswire) +7.22%
Apr-21-21 07:30AM	Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference (GlobeNewswire) +5.75%
Apr-20-21 07:00AM	Cyclerion Therapeutics to Host Pipeline Update Webinar (GlobeNewswire) +7.41%
Mar-24-21 04:05PM	TransMedics Appoints Stephanie Lovell to Board of Directors (PR Newswire) -6.80% +5.78%
Mar-22-21 02:23AM	Are Institutions Heavily Invested In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares? (Simply Wall St.)
Mar-19-21 07:46AM	The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs (Benzinga)
Mar-18-21 05:00PM	Cyclerion Therapeutics Announces Departure of Chief Medical Officer (GlobeNewswire)
Feb-25-21 07:00AM	Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -9.48%
Jan-25-21 07:00AM	Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards (GlobeNewswire)
Jan-21-21 12:52AM	How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The Last Year? (Simply Wall St.)
Jan-04-21 07:00AM	Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-20 07:30AM	Cyclerion Announces Leadership Transitions (GlobeNewswire)
Dec-02-20 11:27PM	Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy? (Insider Monkey)
Nov-15-20 07:55AM	Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More Shares (Simply Wall St.)
Nov-05-20 07:00AM	Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates (GlobeNewswire)
Oct-14-20 01:09PM	Why Cyclerion Therapeutics Is Crashing Today (Motley Fool) -52.95%
10:07AM	Cyclerion Sinks As Biopharma Shelves Sickle Cell Disease Study (Benzinga)
07:00AM	Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects (GlobeNewswire)
07:00AM	Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease (GlobeNewswire)
Oct-04-20 09:52AM	Health Check: How Prudently Does Cyclerion Therapeutics (NASDAQ:CYCN) Use Debt? (Simply Wall St.)
Sep-04-20 07:00AM	Cyclerion to Participate at Upcoming September 2020 Investor Conferences (GlobeNewswire)
Aug-25-20 07:00AM	Cyclerion Announces Translational Research Award from the Alzheimers Association Part the Cloud-Gates Partnership Grant Program (GlobeNewswire) +11.09%
Aug-20-20 11:01AM	Is Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Popular Amongst Institutions? (Simply Wall St.)
Aug-03-20 09:25AM	Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights (GlobeNewswire) +6.81%
Jul-30-20 09:00AM	Cyclerion Therapeutics Completes $24 Million Private Placement (GlobeNewswire) +12.50%
Jul-17-20 07:00AM	Cyclerion Therapeutics Presentation at Biomarkers in Alzheimers Disease Summit (GlobeNewswire)
Jul-06-20 03:17PM	We're A Little Worried About Cyclerion Therapeutics's (NASDAQ:CYCN) Cash Burn Rate (Simply Wall St.)
Jul-05-20 02:45PM	Should You Buy Cyclerion Therapeutics, Inc. (CYCN)? (Insider Monkey)
Jun-18-20 04:01PM	Cyclerion to Host Webcast Investor Event on July 9, 2020 (GlobeNewswire) +18.04%
May-22-20 07:52AM	The Cyclerion Therapeutics (NASDAQ:CYCN) Share Price Is Down 72% So Some Shareholders Are Rather Upset (Simply Wall St.) +6.45%
Apr-10-20 07:00AM	Cyclerion Updates Corporate Progress (GlobeNewswire)
Mar-23-20 06:50AM	Are Insiders Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Stock? (Simply Wall St.) +18.94%
Jan-13-20 07:00AM	Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases (GlobeNewswire) +10.26%
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO (Benzinga)
Dec-24-19 08:17AM	Can Cyclerion Therapeutics (NASDAQ:CYCN) Afford To Invest In Growth? (Simply Wall St.) +6.87%

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.

IVVD

Invivyd Inc

ALEC

Alector Inc

CYCN

Cyclerion Therapeutics Inc

Upgrade your FINVIZ experience